
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE
ACT OF 1934**

For the month of February, 2022.

Commission File Number: 001-40627

SOPHIA GENETICS SA

(Exact name of registrant as specified in its charter)

**Rue du Centre 172
CH-1025 Saint-Sulpice
Switzerland**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒

Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SOPHiA GENETICS SA

Date: February 22, 2022

By: /s/ Daan van Well
Name: Daan van Well
Title: Chief Legal Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated February 22, 2022

First Japanese Institution to Utilize SOPHiA GENETICS' Myeloid Plus Solution

BOSTON, United States, LAUSANNE, Switzerland, and HIROSHIMA, Japan – February 22, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), today announced an agreement with Hiroshima University, one of the top public universities in Hiroshima City, Japan, to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders.

Hiroshima University is home to one of the largest university research institutes in the field of radiation biomedical science in Japan. With NGS for myeloid testing not widely available in Japan, a group of Hiroshima University researchers tapped the SOPHiA DDM Platform to assist with the clinical utility of NGS tests for myeloid malignancies. Hiroshima University aimed to establish a framework where the NGS-based testing would become a routine part of clinical diagnosis for myeloid neoplasms.

Following the adoption of the SOPHiA DDM Platform, Masatoshi Nishizawa from Hiroshima University presented a research case study at the 83rd Annual Meeting of Japanese Society of Hematology (Sendai, September 23-25, 2021). Leveraging the SOPHiA DDM Platform's unique algorithmic capabilities, the researchers from Hiroshima University detailed their experience with the first 24 samples of myeloid solution collected and analyzed as part of a research project to evaluate the clinical utility of NGS testing for myeloid malignancies. The evaluation showed that the SOPHiA DDM platform's unique capabilities in support of NGS testing were both useful and feasible in identifying druggable targets and making precise diagnosis and prognosis to help benefit more patients in Japan. The work of Hiroshima University has since been shared with Japanese laboratories and clinicians, and the university aims to continue its evaluation with additional samples over the next 12 months.

"SOPHiA GENETICS is committed to improving patient outcomes through the practice of data driven medicine. We work with several oncohematology centers around the world and are now eager to start supporting the Japanese oncohematology network of hospitals. The more data we compute, the more benefit we bring to all our users to ultimately accelerate the democratization of data-driven-medicine," said Jurgi Camblong, co-founder and CEO of SOPHiA GENETICS.

"To make a personalized treatment in the real-world practice of oncohematology prevail, the sophistication of diagnostic gene panels is strongly desired," said Tatsuo Ichinohe, Director of the Department of Hematology and Oncology at Hiroshima University Hospital. "SOPHiA GENETICS' Myeloid Plus Solution is one of the best examples I have ever seen in terms of its ease of use and wide coverage."

SOPHiA GENETICS' partnership with Hiroshima University follows the company's March 2021 announcement of a long-term collaboration agreement with Hitachi, Ltd. To bring clinical, genomic, and real-world insights to more Japanese healthcare providers and pharmaceutical and biopharmaceutical companies. In partnership with Hitachi, discussions continue with additional Japanese institutions who may also benefit from SOPHiA GENETICS for oncohematological cancer research.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram. **Where others see data, we see answers.**

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact:

Eliza Bamonti
ebamonti@sophiagenetics.com
